{"database": "lobbying", "table": "lobbying_activities", "rows": [[2815656, "2e005744-91c0-4421-842e-a8b2851d337e", "Q2", "CHAMBER HILL STRATEGIES", 400645947, "BIOMARIN PHARMACEUTICAL INC.", 2022, "second_quarter", "TAX", "Issues generally related to the Orphan Drug Tax Credit, including provisions in H,R. 2623, Camerons Law and H.R. 5376, Build Back Better Act.", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2022-07-08T12:37:01-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2815656"], "units": {}, "query_ms": 0.3245600964874029, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}